Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 7/20 | 0.49 |
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | RARA | P10276 | 2/20 | 0.49 |
| ▸ | RARB | P10826 | 2/20 | 0.49 |
| ▸ | RARG | P13631 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486033 | 0.83 | ALDH1A1 (0.51) | ALDH1A1MEN1MAPTKMT2AOPRK1 | |
| SCHEMBL6971020 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MEN1MAPTKMT2AOPRK1 | |
| SCHEMBL12844164 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MEN1MAPTKMT2AOPRK1 | |
| SCHEMBL12775968 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MEN1MAPTKMT2AOPRK1 | |
| SCHEMBL14736417 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MEN1MAPTKMT2AOPRK1 | |
| SCHEMBL15728787 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MAPTHSD17B10AR | |
| SCHEMBL14736416 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MEN1MAPTKMT2AOPRK1 | |
| Hydrochloric Acid SCHEMBL14736655 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MEN1MAPTKMT2AOPRK1 | |
| SCHEMBL2226979 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MEN1MAPTKMT2AOPRK1 | |
| SCHEMBL18134384 | 0.78 | XIAP (0.48) | ALDH1A1MEN1MAPTKMT2AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828360-B2 | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160297796-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-13 | — | — | US | disclosed |
| EP-2354134-B1 | 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| CN-102239164-B | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC | 2013-10-30 | — | — | CN | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| CN-102239164-A | 2h-chromene compound and derivative thereof | ASTELLAS PHARMA INC | 2011-11-09 | — | — | CN | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2354134-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | Astellas Pharma Inc. (JP) | 2011-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297796-A1 | PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | TK1, UACA, TYMP | ALDH1A1 3113/4885MEN1 3667/4885MAPT 544/4885 |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | ALDH1A1 2201/4885MEN1 1528/4885MAPT 4495/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | ALDH1A1 2294/4885MEN1 2001/4885MAPT 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.